Baseline patient and disease characteristics by treatment arm
| Characteristic . | Pacritinib . | ||
|---|---|---|---|
| 100 mg once per d (n = 52) . | 100 mg twice per d (n = 55) . | 200 mg twice per d (n = 54) . | |
| Median age (IQR), y | 69.5 (64.0-74.0) | 69.0 (66.0-73.0) | 68.5 (62.0-73.0) |
| Male sex | 31 (59.6) | 29 (52.7) | 32 (59.3) |
| Myelofibrosis diagnosis | |||
| Primary | 28 (53.8) | 28 (50.9) | 37 (68.5) |
| Post polycythemia vera | 16 (30.8) | 18 (32.7) | 10 (18.5) |
| Post essential thrombocythemia | 8 (15.4) | 9 (16.4) | 7 (13.0) |
| Previous ruxolitinib treatment | |||
| Failure | 40 (76.9) | 41 (74.5) | 42 (77.8) |
| Intolerance | 38 (73.1) | 41 (74.5) | 38 (70.4) |
| Both | 26 (50.0) | 28 (50.9) | 26 (48.1) |
| Median duration of previous ruxolitinib treatment (IQR), y | 1.7 (0.7-3.0) | 1.8 (0.8-3.5) | 1.6 (0.4-3.3) |
| DIPSS risk score* | |||
| Intermediate-1 | 9 (17.3) | 14 (25.5) | 12 (22.2) |
| Intermediate-2 | 25 (48.1) | 27 (49.1) | 28 (51.9) |
| High | 18 (34.6) | 14 (25.5) | 14 (25.9) |
| ECOG PS | |||
| 0 | 11 (21.2) | 14 (25.5) | 17 (31.5) |
| 1 | 32 (61.5) | 29 (52.7) | 29 (53.7) |
| 2 | 9 (17.3) | 12 (21.8) | 8 (14.8) |
| Platelet count, × 103/μL | |||
| Median (IQR) | 59 (41 -111 ) | 53 (33 -116 ) | 59 (29 -91 ) |
| <50 | 23 (44.2) | 24 (43.6) | 24 (44.4) |
| Hemoglobin <10g/dL | 35 (67.3) | 38 (69.1) | 41 (75.9) |
| RBC transfusion status† | |||
| Dependent | 15 (28.8) | 15 (27.3) | 21 (38.9) |
| Independent | 24 (46.2) | 23 (41.8) | 20 (37.0) |
| Intermediate | 13 (25.0) | 16 (29.1) | 13 (24.1) |
| Platelet transfusion dependent‡ | 6 (11.5) | 5 (9.1) | 6 (11.1) |
| Peripheral blasts ≥1% | 32 (61.5) | 30 (54.5) | 32 (59.3) |
| Median peripheral blasts (IQR), % | 2.0 (1.0-3.0) | 2.0 (0.9-4.0) | 2.0 (1.0-2.0) |
| Median white blood cell (IQR), ×109/L | 10.9 (4.9-34.9) | 7.8 (3.5-18.6) | 7.1 (4.2-12.6) |
| Median spleen length (IQR), cm | 12.0 (9.5-19.5) | 15.0 (11.0-20.0) | 14.0 (10.0-20.0) |
| Median spleen volume (IQR), cm3 | 2434 (1694-3041) | 2169 (1651-2839) | 2655 (1630-4069) |
| Characteristic . | Pacritinib . | ||
|---|---|---|---|
| 100 mg once per d (n = 52) . | 100 mg twice per d (n = 55) . | 200 mg twice per d (n = 54) . | |
| Median age (IQR), y | 69.5 (64.0-74.0) | 69.0 (66.0-73.0) | 68.5 (62.0-73.0) |
| Male sex | 31 (59.6) | 29 (52.7) | 32 (59.3) |
| Myelofibrosis diagnosis | |||
| Primary | 28 (53.8) | 28 (50.9) | 37 (68.5) |
| Post polycythemia vera | 16 (30.8) | 18 (32.7) | 10 (18.5) |
| Post essential thrombocythemia | 8 (15.4) | 9 (16.4) | 7 (13.0) |
| Previous ruxolitinib treatment | |||
| Failure | 40 (76.9) | 41 (74.5) | 42 (77.8) |
| Intolerance | 38 (73.1) | 41 (74.5) | 38 (70.4) |
| Both | 26 (50.0) | 28 (50.9) | 26 (48.1) |
| Median duration of previous ruxolitinib treatment (IQR), y | 1.7 (0.7-3.0) | 1.8 (0.8-3.5) | 1.6 (0.4-3.3) |
| DIPSS risk score* | |||
| Intermediate-1 | 9 (17.3) | 14 (25.5) | 12 (22.2) |
| Intermediate-2 | 25 (48.1) | 27 (49.1) | 28 (51.9) |
| High | 18 (34.6) | 14 (25.5) | 14 (25.9) |
| ECOG PS | |||
| 0 | 11 (21.2) | 14 (25.5) | 17 (31.5) |
| 1 | 32 (61.5) | 29 (52.7) | 29 (53.7) |
| 2 | 9 (17.3) | 12 (21.8) | 8 (14.8) |
| Platelet count, × 103/μL | |||
| Median (IQR) | 59 (41 -111 ) | 53 (33 -116 ) | 59 (29 -91 ) |
| <50 | 23 (44.2) | 24 (43.6) | 24 (44.4) |
| Hemoglobin <10g/dL | 35 (67.3) | 38 (69.1) | 41 (75.9) |
| RBC transfusion status† | |||
| Dependent | 15 (28.8) | 15 (27.3) | 21 (38.9) |
| Independent | 24 (46.2) | 23 (41.8) | 20 (37.0) |
| Intermediate | 13 (25.0) | 16 (29.1) | 13 (24.1) |
| Platelet transfusion dependent‡ | 6 (11.5) | 5 (9.1) | 6 (11.1) |
| Peripheral blasts ≥1% | 32 (61.5) | 30 (54.5) | 32 (59.3) |
| Median peripheral blasts (IQR), % | 2.0 (1.0-3.0) | 2.0 (0.9-4.0) | 2.0 (1.0-2.0) |
| Median white blood cell (IQR), ×109/L | 10.9 (4.9-34.9) | 7.8 (3.5-18.6) | 7.1 (4.2-12.6) |
| Median spleen length (IQR), cm | 12.0 (9.5-19.5) | 15.0 (11.0-20.0) | 14.0 (10.0-20.0) |
| Median spleen volume (IQR), cm3 | 2434 (1694-3041) | 2169 (1651-2839) | 2655 (1630-4069) |
All data are no. (%) unless otherwise specified.
DIPSS, Dynamic International Prognostic Scoring System; ECOG PS, Eastern Cooperative Oncology Group performance status; IQR, interquartile range.
High molecular risk as defined by Tefferi et al.16
RBC transfusion status as defined by Gale criteria.28
Platelet transfusion dependence defined by any platelet transfusion required during the past month.